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Abstract
The objective of this prospective study was to evaluate the efficacy
and complications of the use of an intraocular sustained-release
ganciclovir implant for the treatment of active cytomegalovirus (CMV)
retinitis in AIDS patients. Thirty-nine eyes of 26 patients were submit-
ted to ocular surgery. All patients underwent complete ocular exami-
nation before and after surgery. The surgical procedure was always
done under local anesthesia using the same technique. The mean time
for the surgical procedure was 20 min (range, 15 to 30 min). The
average follow-up period was 3.7 months. Of all patient, only 4
presented recurrence of retinitis after 8, 8, 9 and 2 months, respec-
tively. Three of them received a successful second implant. All 39 eyes
of the 26 patients presented healing of retinitis as shown by clinical
improvement evaluated by indirect binocular ophthalmoscopy and
retinography. Retinitis healed within a period of 4 to 6 weeks in all
patients, with clinical regression signs from the third week on. Six
(15.4%) eyes developed retinal detachment. None of the patients
developed CMV retinitis in the contralateral eye. The intraocular
implant proved to be effective in controlling the progression of
retinitis for a period of up to 8 months even in patients for whom
systemic therapy with either ganciclovir or foscarnet or both had
failed. The intraocular sustained-release ganciclovir implant proved to
be a safe new procedure for the treatment of CMV retinitis, avoiding
the systemic side effects caused by the intravenous medications and
improving the quality of life of the patients.
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Introduction
Acquired immunodeficiency syndrome
(AIDS) is a fatal disease caused by the hu-
man immunodeficiency virus (HIV), charac-
terized by lymphocytopenia, development of
secondary infections and tumors (1). In Bra-
zil, according to the survey of the 1998 Epi-
demiology Bulletin of the Ministry of Health
(National Program of Sexually Transmis-
sible Diseases/AIDS) for the period from
1980 to 1998, a total of 150,000 cases of
AIDS were reported, including adults, ado-
lescents and children under 15 years (2). The
survival of HIV-infected patients is increas-
ing, mostly due to the use of antiretroviral
therapy and better control of AIDS-related
opportunistic infections (3). In 1992, the
Centers for Disease Control (CDC) revised
its classification system for HIV infection,
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emphasizing the importance of CD4 cell
count in order to categorize the HIV-related
clinical conditions. The system is based on
the presence of HIV-specific positive serol-
ogy and on three clinical categories and three
CD4 values (4). HIV virulence is the result
of its debilitating effect on the immune sys-
tem, rendering the patient vulnerable to in-
fections and malignancies (5). One example
of these infections is cytomegalovirus (CMV)
retinitis, a late stage AIDS manifestation
which develops in patients with severe im-
munodeficiency (6). This opportunistic in-
fection is an indicator of a disease fulfilling
CDC criteria for AIDS diagnosis. Before
1982, CMV retinitis was a very rare disease
occurring usually after chemotherapy as a
consequence of immunological depression
(7). CMV infection in immunocompetent
patients seldom leads to ocular impairment,
with only two reports in the literature (8).
With the advent of the AIDS pandemic, CMV
retinitis has become one of the most impor-
tant causes of infectious retinitis all over the
world (9,10). Research on CMV and related
diseases was first described in 1921 by
Goodpasture and Talbot (11) who coined the
term cytomegaly to describe the presence of
large mononuclear inclusions found at au-
topsy in several organs of children (11,12).
The spectrum of diseases known to be
caused by CMV expanded in 1965 when
Klemola and Kaariainen (13) described the
mononucleosis-like CMV infection syn-
drome in adult immunocompetent patients.
During the following years CMV became
more important because it was a frequent
opportunistic pathogen in the immunode-
pressed. The increasing number of organ
and medulla transplants and an increase in
the use of immunosuppressants were associ-
ated with the presence of pneumonitis, coli-
tis, hepatitis, encephalitis, retinitis and other
diseases due to CMV in these patients. Since
1981 CMV has been recognized as the most
important opportunistic infection in AIDS
patients (14).
The first published series of AIDS-re-
lated ocular disease already described CMV
retinitis as a complication of the syndrome
(15-17). In AIDS patients, CMV primarily
infects the retina, but some papers have re-
ported infection of other ocular structures
such as cornea, conjunctiva, iris and ciliary
body (18). CMV retinitis is the most com-
mon ocular infection in AIDS patients and
the main cause of their blindness, affecting
approximately 30 to 50% of these patients in
different countries, including Brazil (19,20).
The only risk factor clearly associated with
the development of CMV retinitis in HIV-
infected patients is the low number of T CD4
lymphocytes. Retinitis almost always appears
at levels below 100 cells/mm3 and the risk is
higher when the number is below 50 cells/
mm3 (21,22). The diagnosis of CMV retini-
tis is based on the clinical aspect of the lesion
but there are atypical cases requiring labora-
tory studies to establish the diagnosis (23,24).
Pannuti et al. (25) in 1996 used cell cul-
ture and the antigenemia test for CMV in
patients with AIDS and CMV retinitis with-
out previous treatment and concluded that
patients with AIDS and active CMV had
active replication of peripheral leukocytes
and could benefit from this auxiliary exam in
their treatment.
The retinitis is necrotizing, with white-
yellowish areas, varying degrees of hemor-
rhage and vasculitis. Anterior chamber and
vitreous inflammation is usually light with-
out formation of posterior synechiae. Retini-
tis may be uni- or bilateral, but cases present-
ing with unilateral disease have a high risk of
second eye involvement, probably due to
hematogenic dissemination. Spontaneous re-
mission is extremely rare and possibly re-
lated to improvement in immunity (26).
The first, classical pattern of CMV retini-
tis, called hemorrhagic, is characterized by
retinal areas with a granular, whitish and
hemorrhagic aspect, usually with lesions
close to the vascular arcades or to the optic
nerve, and subretinal exudation. The retinal
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vessels in the necrotic area may be sheathed
by vasculitis and consequently present reti-
nal vascular, especially venous, occlusions.
Central healing of the lesions occurs after
necrosis, leading to atrophy of the retina and
choroid (27).
The second pattern of retinitis is the granu-
lar or atypical one. The retina shows granu-
lar focal infiltrates which increase linearly
and slowly, leaving areas of retinal destruc-
tion with an atrophic retinal pigmentary epi-
thelium allowing to observe details of the
choroid. Retinal hemorrhages and vitreous
cells usually are absent on biomicroscopy in
this retinitis pattern (14).
The third pattern, more rarely observed,
associated or not with the classical hemor-
rhagic form is characterized by severe vas-
culitis, with intense sheathing shown by ar-
teries and veins, resembling frosted branch
angiitis (14).
Complications of retinitis include retinal
detachment which occurs in 17 to 34% of the
patients. Posterior vitrectomy, followed by
intraocular injection of silicone oil, and
endolaser application is the present treat-
ment technique (28,29).
Before 1985, patients with CMV retinitis
had a very poor visual prognosis. Several
pharmacological treatments, including
vidarabine, acyclovir, alpha-interferon and
interleukin-2 had been tried without success
(30). Since 1989, with the release of
ganciclovir for intravenous use in the US,
the natural history of the disease has changed.
Foscarnet, in 1991, was approved for intra-
venous use in the US and more recently, in
1996, another antiviral, called cidofovir, was
approved. To date, only these 3 drugs have
been approved by the Food and Drug Ad-
ministration (FDA - USA) and are available
for treatment of CMV retinitis (31). All are
virostatic and, when applied intravenously,
cause important side effects: neutropenia by
ganciclovir and renal toxicity by foscarnet
and cidofovir. Treatment with any of the
drugs should initially use a loading dose for
2 to 3 weeks and then a maintenance dose for
the rest of the life of the patient, leading to a
significant worsening in the quality of life,
the patient not being able to work and to
carry out the usual activities of everyday life
(14,31).
Ganciclovir activity against human CMV
primarily results in inhibition of viral DNA
synthesis. It competitively inhibits dGTP in-
corporation into DNA and is also directly
incorporated into viral DNA, blocking the
completion of its formation (14). Mainte-
nance therapy with ganciclovir is necessary
to control progression of the disease. Even in
patients under maintenance therapy, retinitis
may progress, often requiring reinduction
(14).
Due to the potentially irreversible side
effects, or to the absence of response to
intravenous treatment, several studies were
performed using intravitreous ganciclovir in-
jections for local treatment (31). Local thera-
pies are efficient in CMV retinitis treatment,
but their relative risks and benefits, when
compared with those of intravenous therapy,
need to be clarified. Local therapy will be an
important treatment modality for some se-
lected patients with CMV retinitis. Indica-
tions include patients who are unable to
receive intravenous therapy and as a supple-
ment in patients whose retinal disease is not
completely controlled using maximum toler-
ated systemic medication. Perhaps the best
use of local therapy is in association with
oral forms (30).
The literature started to report the experi-
ence with the use of ganciclovir implants for
the treatment of CMV retinitis in 1992. Such
implants consisted of a polymer base with a
platform allowing programmed release of
the drug, which was placed surgically in the
posterior ocular chamber (32). Anand et al.
(33) in 1993 reported their experience with
these implants in a sample of 22 patients (30
eyes). No severe complications associated
with the implant were observed, except for
one patient who developed endophthalmitis.
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The authors concluded that this was an effi-
cient form to treat CMV retinitis.
In the anatomopathological study, Anand
et al. (34) observed that the intraocular im-
plant was efficient in retinitis control and
that the clinical and pathological results were
similar to those observed in eyes of patients
who were treated with intravenous ganciclo-
vir. In addition, they observed the absence of
side effects or local toxicity.
In 1994, results of a randomized clinical
study carried out in the US using the same
type of implant and the same surgical tech-
nique were published, confirming the results
of former studies and proving the efficacy of
this therapeutic procedure. The study in-
cluded 26 patients (30 eyes) with CMV re-
tinitis divided into two groups: one receiving
immediate treatment and the other, late treat-
ment. All patients were treated with ganci-
clovir implants with a release rate of 1 µg/h.
In this series of patients there was clinical
improvement and complete healing of the
lesions, confirming the results of former stud-
ies and showing that this is an efficient thera-
peutic modality for the treatment of CMV
retinitis (35).
The purpose of the present study was to
analyze the efficacy of intraocular implants
of sustained release of ganciclovir for the
treatment of CMV retinitis in AIDS patients
and their complications.
Patients, Material and Methods
A clinical prospective study on 39 eyes
of 26 patients with AIDS and with a clinical
diagnosis of CMV retinitis was performed
over a period of one year.
The protocol was approved by the Medi-
cal Ethics Committee of Universidade Fed-
eral de Sªo Paulo (Escola Paulista de Medi-
cina) and Hospital Sªo Paulo, which autho-
rized the use of an experimental drug, per-
mitted by the Ministry of Health, according
to a Resolution of the National Health Coun-
cil.
Three of the 26 patients (11.5%) were
submitted to placement of two implants in
the same eye. AIDS diagnosis was based on
the definition of AIDS, as revised by the
CDC (4). The patients were referred by phy-
sicians, from different institutions. All pa-
tients were submitted to clinical and sero-
logical evaluation before the study and
throughout the postoperative period, at
monthly intervals.
Inclusion criteria were: AIDS diagnosis
according to CDC criteria, active CMV re-
tinitis in the eye to be treated, clinical wors-
ening of CMV retinitis after intravenous treat-
ment with ganciclovir or foscarnet, signed
written consent form, and availability to ap-
pear for the returns required by the protocol.
Exclusion criteria were: absence of pre-
vious intravenous treatment with ganciclovir
or foscarnet, retinal detachment in the eye to
be treated, previous eye disease, hypersensi-
tivity to ganciclovir or foscarnet, pregnancy,
lactation, and indication for intravenous use
of ganciclovir or foscarnet.
During each visit, all patients were sub-
mitted to a complete ophthalmological ex-
amination which consisted of measurement
of best corrected visual acuity according to
Snellens chart, ectoscopy, biomicroscopy,
applanation tonometry, and indirect binocu-
lar ophthalmoscopy under drug-induced
mydriasis.
Specific examinations, such as retinogra-
phy, angiofluoresceinography, ultrasonog-
raphy and ultrasound biometry were per-
formed when required.
The diagnosis of CMV retinitis was es-
tablished and the response to treatment was
evaluated through ophthalmoscopic exami-
nation. The following parameters were stud-
ied: the best corrected visual acuity, number,
localization and extension of the lesions.
Localization and progression of the lesions
were determined using the retinal area scheme
standardized by Holland et al. (36), which
divides the retina into three zones: (scheme
1) zone 1: retinal area located within 3,000
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µm of the fovea or 1,500 µm from the optic
nerve; zone 2: retinal area extending from
the border of zone 1 to the anterior border of
the vorticose veins; zone 3: retinal area ex-
tending from the border of zone 2 to the ora
serrata. The extension of the lesion was esti-
mated using the following semiquantitative
evaluation: less than 10% of the retina in-
volved, 11 to 25% of the retina involved, 26
to 50% of the retina involved, over 50% of
the retina involved. As reference, the macula
was considered to be approximately 5% of
the whole area of the retina.
Worsening was defined as progression,
increase in number and/or area of CMV
retinitis lesions according to examination of
the retina by two ophthalmologists. Improve-
ment was defined as increased granular as-
pect of the involved retina, mainly at the
border and the progressive demarcation and
interruption of the area of lesion growth.
Sustained-release ganciclovir implants
(Vitrasert, Chiron Vision, Claremont, NH,
USA) placed in the vitreous cavity consisted
of a polymer with a drug release system.
They contained approximately 6 mg of
ganciclovir in a 1-mm thick tablet measuring
2.5 mm in diameter covered on all sides with
30 µl 10% polyvinyl alcohol (PVA) (perme-
able polymer) and wrapped in a discontinu-
ous, prepressed film of ethylenevinyl acetate
(EVA) (impermeable polymer). The whole
structure was covered again with PVA. The
EVA cover was impermeable to ganciclovir
while the semipermeable PVA cover allowed
diffusion of the drug. The implants were
then wrapped again in a 3-mm 10% PVA
disk, sterilized with ethylene oxide and placed
in individual sterile packages. The expected
rate of release was 1 µg/h.
Peribulbar anesthesia was performed us-
ing approximately 2 ml 2% lidocaine (Xylo-
cainefi) with a vasoconstrictor and 2 ml 0.75%
bupivacaine (Marcainefi) without a vaso-
constrictor. A limbic conjunctival incision
in the lower temporal quadrant was made,
with hemostasis of episcleral and conjuncti-
val vessels. The intravitreous implant was
prepared, and a 6.0-mm scleral incision was
made 4 mm from and parallel to the limbus,
exposing the choroid. The implant was su-
tured to the sclera with a single suture of 9.0
mononylon Ethiconfi. External vitrectomy
was performed and the implant was placed
in the vitreous cavity under microscopic con-
trol to ascertain its correct position. The
incision was closed with continuous Ethiconfi
mononylon 9.0 sutures. The conjunctiva was
then sutured and 10 mg gentamicin and 1 mg
dexamethasone were injected subconjuncti-
vally.
Surgeries lasted 15 to 30 min, with a
mean of 20 min, without any transoperative
complication. Adequate position of the im-
plant was confirmed by direct observation
through the dilated pupil by slight scleral
depression.
The patients were discharged immedi-
ately after being liberated by the anesthesi-
ologist.
The eye was occluded for 12 to 24 h. The
patient took an antibiotic and a corticoid 4
times daily for 2 weeks and a topic mydriatic
preparation every 12 h for 3 days.
Postoperative evaluations were made on
days 1, 3, 7, 15, 30 and monthly after the first
month for the next 12 months.
Results
The age of the patients ranged from 26 to
47 years, with a mean of 35.2 years. Three
patients (11.5%) were females and 23
(88.5%) males. Follow-up ranged from 30
days to 9 months (date of the last eye exami-
nation), with a mean of 3.7 months. In 8 eyes
of 7 patients (18%) this time was 6 months or
longer.
Of the 3 patients who developed extraocu-
lar CMV, one had intestinal CMV, one CMV
pneumonia and one ascending CMV myeli-
tis. All were referred for intraocular implant
placement because they presented severe neu-
tropenia and contraindication for intrave-
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nous treatment with the dose required for
retinitis treatment.
Of the total of 39 operated eyes, 6 (15.4%)
presented less than 10% retinal involvement,
18 (46.1%) between 10 and 24%, 11 (28.2%)
between 25 and 49%, and 4 (10.3%) over
50%. Twelve eyes (30.8%) presented retinal
lesion located in zone 1, 8 (20.5%) in zone 2,
4 (10.3%) in zone 3, 2 (5.1%) in zones 1 and
2, 6 (15.4%) in zones 2 and 3, and 7 (17.9%)
in zones 1, 2 and 3 (Table 1).
Twenty patients (77%) presented bilat-
eral retinitis and 6 (23%) unilateral retinitis.
Of those who presented bilateral retinitis, 10
(50%) had both eyes surgically treated and
10 (50%) received the implant in only one
eye. Although presenting CMV retinitis in
both eyes, they received the implant in only
one eye because of the following situations
in the fellow eye: visual acuity limited to
light perception, optic atrophy, retinal de-
tachment and blindness. In 3 patients (11.5%)
a second implant was placed in the same eye.
No patient developed intraocular infec-
tion or severe uveitis. Some eyes presented 1
or 2+ cells in the anterior chamber during the
first weeks after surgery, returning to the
situation before surgery after 1 or 2 weeks.
Indirect ophthalmoscopy during the first
weeks showed absence of detachment of the
retina or choroid.
Of all patients, only 4 presented retinitis
relapse after 8, 8, 9 and 2 months, respec-
tively. Three of them received a successful
second implant. One patient did not receive
the second implant because he developed
very severe CMV retinitis and visual acuity
of no light perception. All 39 eyes of the 26
patients presented healing of the retinitis
expressed by clinical improvement as evalu-
ated by indirect binocular ophthalmoscopy
and as confirmed by retinography. Retinitis
healed within 4 to 6 weeks in all patients,
with clinical signs of regression from the
third week on. Of the 39 operated eyes, 13
(33.3%) maintained the same visual acuity
from the preoperative to the last examina-
tion, 13 eyes (33.3%) showed improved vi-
sual acuity, and 13 eyes (33.3%) showed a
worse visual acuity (Table 2).
Of the eyes with improved vision, 7 (18%)
improved by 2 or more lines of visual acuity
and 6 (15.4%) improved by 1 line. Of those
who had worse vision, 6 (15.4%) worsened
by l line and 7 worsened by 2 or more lines of
visual acuity. Causes of vision worsening
were retinal detachment, central nervous sys-
tem involvement (neurotoxoplasmosis and
neurocryptococcosis), and severe and abrupt
recurrence.
Mean preoperative ocular pressure was
10.4 mmHg (SD 1.5) and mean 30-day post-
operative ocular pressure was 11.2 mmHg
(SD 2.9). No pressure below 6 mmHg, above
20 mmHg or chronic ocular hypotonia was
observed.
Six eyes (15.4%) of 6 patients (23%)
presented retinal detachment, three of them
during the third month after surgery (pa-
tients number 2, 7 and 26). The others devel-
oped it during the first (patient 18), second
(patient 11) and fourth (patient 14) month.
The areas of retinitis involvement of these
patients were zone 3 in 4 eyes (patients 2, 7,
11, and 26) and zone 1, 2 and 3 in 2 eyes
(patients 14 and 18).
The patients were submitted to posterior
vitrectomy, with retinopexy, endophotoco-
agulation and silicone oil injection. All pa-
tients submitted to retinopexy progressed to
cured retinal detachment, without relapse of
CMV retinitis or need for implant removal.
No patient developed CMV retinitis in the
contralateral eye.
Three eyes of three patients with relapses
of CMV retinitis received a second implant
using the same technique and without com-
plications. The implants were placed in the
nasal quadrant and no complications oc-
curred. The time before relapse was 8, 8 and
9 months for patients 6, 7 and 10, respec-
tively.
Three patients (11.2%) developed ex-
traocular CMV and were treated with main-
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Table 1 - Patient, eye, pre-operative visual acuity, presence of cytomegalovirus (CMV) retinitis and retinal
involvement.
RE = Right eye; LE = left eye; visual acuity pre-RE = pre-operative visual acuity in the RE; visual acuity pre-LE
= pre-operative visual acuity in the LE; Zone RE = retinal involvement in RE; Zone LE = retinal involvement in
LE; Area %RE = percentage of retinal involvement in RE; Area %LE = percentage of retinal involvement in LE;
CF 1 m, 2 m and 3 m = visual acuity of finger counts at 1, 2 or 3 m, respectively; HM = visual acuity of hand
movements; N/LP = visual acuity of no light perception; LP = visual acuity of light perception.
Patient/eye Visual acuity CMV retinitis Zone Area
pre-RE pre-LE RE LE RE LE %RE %LE
1 RE CF 1 m LP Yes Yes 1, 2, 3 1, 2, 3 >50 >50
2 RE 20/40 20/20 Yes No 2, 3 - 25-49 -
3 LE 20/25 20/20 Yes Yes 2 2 10-24 10-24
RE 20/25 20/20 Yes Yes 2 2 10-24 10-24
4 LE 20/25 20/25 Yes Yes 3 3 <10 <10
RE 20/25 20/25 Yes Yes 3 3 <10 <10
5 LE HM 20/30 Yes Yes 1, 2, 3 2 >50 10-24
6 RE 20/40 20/20 Yes No 2 - 25-49 -
RE 20/30 20/20 Yes No 2, 3 - 25-49 -
7 LE N/LP 20/80 Yes Yes 1, 2, 3 1 >50 10-24
LE N/LP 20/100 Yes Yes 1, 2, 3 1 >50 10-24
8 LE HM CF 3 m Yes Yes 1, 2, 3 1, 2, 3 >50 >50
9 RE 20/40 20/30 Yes Yes 1, 2, 3 1 25-49 10-24
LE 20/100 20/25 Yes Yes 1, 2, 3 1 25-49 10-24
10 LE 20/20 20/25 No Yes - 2 - 25-49
LE 20/20 20/30 No Yes - 2 - 25-49
11 LE 20/20 20/20 Yes Yes 1 1 10-24 10-24
RE 20/20 20/60 Yes Yes 1 1 10-24 10-24
12 RE 20/40 20/25 Yes Yes 1 1, 2 10-24 10-24
13 RE 20/20 20/20 Yes No 1 - <10 -
14 RE 20/25 20/25 Yes Yes 1 1 10-24 10-24
LE 20/80 20/25 Yes Yes 1 1 10-24 10-24
15 RE 20/80 20/40 Yes Yes 2, 3 2, 3 10-24 10-24
LE 20/60 20/40 Yes Yes 2, 3 2, 3 10-24 10-24
16 RE 20/60 LP Yes Yes 1, 2, 3 1, 2, 3 25-49 >50
17 LE CF 2 m 20/80 Yes Yes 1, 2, 3 1, 2, 3 >50 25-49
18 LE N/LP CF 3 m Yes Yes 1, 2, 3 1, 2, 3 >50 >50
19 LE 20/60 20/20 Yes Yes 1, 2 2 10-24 10-24
RE 20/60 20/20 Yes Yes 1, 2 2 10-24 10-24
20 RE 20/400 20/20 Yes No 1 - <10 -
21 LE 20/40 20/60 Yes Yes 2, 3 2, 3 25-49 25-49
RE 20/40 20/60 Yes Yes 2, 3 2, 3 25-49 25-49
22 RE 20/30 20/20 Yes Yes 1 3 10-24 <10
LE 20/30 20/20 Yes Yes 1 3 10-24 <10
23 RE 20/20 20/20 Yes No 2 - 10-24 -
24 LE 20/30 20/20 Yes Yes 1, 2 1 25-49 10-24
25 LE N/LP CF 1 m Yes Yes 1, 2, 3 1, 2, 3 >50 >50
26 RE 20/60 20/60 Yes Yes 1, 2 3 25-49 <10
LE 20/60 20/30 Yes Yes 1, 2 3 25-49 <10
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Table 2 - Patient, eye and pre-operative visual acuity, after 1 day, 1 month,
final, and follow-up period (in months).
For abbreviations, see legend to Table 1.
Patient/eye Visual acuity Follow-up
(months)
Pre-op Day 1 1 month Final
1 RE CF 1 m CF 1 m CF 1 m CF 1 m 1
2 RE 20/40 20/25 20/20 20/400 4
3 LE 20/20 20/20 20/60 20/60 2
RE 20/25 missed 20/100 20/100 2
4 LE 20/25 20/30 20/30 20/30 4
RE 20/25 20/40 20/40 20/40 4
5 LE 20/30 20/25 20/20 20/20 1
6 RE 20/40 20/200 20/40 20/30 8
RE 20/30 20/25 20/30 20/25 4
7 LE 20/80 20/40 20/30 20/100 8
LE 20/100 20/100 20/100 20/100 2
8 LE CF 3 m CF 3 m CF 3 m CF 3 m 1
9 RE 20/40 20/100 20/20 20/20 6
LE 20/25 20/25 20/20 20/20 6
10 LE 20/25 20/100 20/30 20/30 9
LE 20/30 20/25 20/25 20/25 4
11 LE 20/20 20/200 HM 20/20 7
RE 20/20 20/20 20/20 CF 3 m 3
12 RE 20/40 20/60 20/20 20/20 1
13 RE 20/20 20/40 20/20 20/20 1
14 RE 20/25 20/80 20/20 20/200 4
LE 20/25 20/60 20/20 20/20 4
15 RE 20/80 20/60 20/40 20/60 5
LE 20/40 20/40 20/30 20/25 5
16 RE 20/60 20/100 20/100 20/100 2
17 LE 20/80 20/80 20/20 20/40 8
18 LE CF 3 m CF 3 m CF 3 m HM 2
19 LE 20/20 20/20 20/20 20/20 4
RE 20/60 20/100 20/80 20/60 4
20 RE 20/400 20/400 20/200 20/200 4
21 LE 20/60 20/60 20/200 20/60 1
RE 20/40 20/80 20/40 20/40 1
22 RE 20/30 20/30 20/30 20/20 4
LE 20/20 20/25 20/25 20/20 4
23 RE 20/20 20/50 20/20 20/20 2
24 LE 20/20 20/60 20/25 20/20 4
25 LE CF 1 m CF 2 m CF 2 m N/LP 2
26 RE 20/60 20/60 20/20 20/70 6
LE 20/25 20/25 20/20 20/20 5
tenance doses of intravenous ganciclovir of
5 mg kg-1 day-1 twice a week.
Discussion
CMV retinitis is one of the most impor-
tant complications of AIDS, which can af-
fect 6 to 38% of these patients and may be
bilateral in 30 to 50% with up to 25% of the
affected patients possibly losing their vision
(9,14). During the first decade of the epi-
demic, options for prophylaxis and treat-
ment of CMV retinitis were very limited.
During the last 5 years, several new treat-
ment options have been studied and have
proved to be efficient, safe and easy to ad-
minister.
The patients included in this study pre-
sented relapsing CMV retinitis, of difficult
control by intravenous treatment. Before the
implant, all patients had been submitted to at
least one induction treatment with intrave-
nous ganciclovir or foscarnet and were un-
successfully receiving intravenous mainte-
nance treatment with one of the two drugs. It
is known that relapses may occur due to
inadequate doses or frequency of injections
or to marked immunodepression, since the
virus remains latent in retinal cells. Usually
they are manifested by the presence of an
active border in the formerly healed lesion,
suggesting that the predominant factor is the
reactivation of the latent virus and not sys-
temic reinfection.
In this study CMV retinitis healing was
observed from the 15th day after surgery for
implant placement and all patient had healed
retinitis after the first postoperative month.
Healing of the lesions was observed even in
those patients with a suspicion of viral resis-
tance to intravenous ganciclovir or foscarnet.
CMV retinitis relapse is common during
maintenance therapy, occurring in approxi-
mately 85% of the patients. Mean recurrence
time, evaluated by clinical observation, is 84
days for patients treated with intravenous
ganciclovir, and 74 days for those treated
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with intravenous foscarnet (14). Anand et al.
(33) analyzed the mean progression time for
CMV retinitis in 30 eyes which received the
intraocular ganciclovir implant and observed
that this time was 19 weeks (133 days), a fact
that confirms its advantage when compared
with intravenous treatments. Mean progres-
sion time of CMV retinitis with an intraocu-
lar ganciclovir implant in patients with pe-
ripheral lesions and immediate treatment was
225 days as compared with 15 days in pa-
tients chosen for late treatment (35).
In the present study, 4 patients (15.4%)
developed CMV retinitis relapse. In two of
them this relapse occurred during the eighth
month (240 days), in one during the ninth
month (270 days) and in the fourth, during
the second month (60 days). The reasons
why the fourth patient relapsed so early are
unknown, but were probably related to the
severity of ocular disease and the marked
immunosuppression of this patient.
Marx et al. (37) in 1996 reported their
experience with intraocular ganciclovir im-
plants in patients with relapsing CMV retini-
tis. They treated 91 eyes of patients who had
already been treated with an intravenous
drug (ganciclovir or foscarnet). In the study
by these authors, 76% of the patients re-
sponded to treatment with an intraocular
implant within 1 month and 64% of them did
not develop relapse during the study.
In the present study, 100% of the patients
had their retinitis healed within the first month
and only 15.4% suffered a relapse. This
study included patients previously using in-
travenous ganciclovir and thus possibly pre-
senting viral resistance, in contrast to other
literature studies (38). Antiviral sensitivity
was not determined. The high mortality at
the time of this study did not allow observa-
tion of long-term results.
Ganciclovir implants present a series of
advantages such as the presence of a con-
stant drug level which may prevent viral repli-
cation during maintenance with subtherapeu-
tic levels as well as viral resistance (39).
Patients presenting relapse or new le-
sions may receive another implant. Morley
et al. (40) reported their experience with 9
eyes which received two or more implants
after presenting relapse of the lesion, except
for one patient who received the new im-
plant after the seventh month due to an in-
crease of the preexisting lesion. Patients who
received the second implant in the same
surgical incision as the first had the implant
removed and the new one placed by the same
surgical technique. Other patients received
the implant in the upper quadrant or in the
same quadrant, with an extension of the first
incision. The authors concluded that mul-
tiple implants can be used without complica-
tions, with a good visual prognosis and con-
trol of CMV retinitis.
In the present study, 3 patients (11.5%)
who developed relapse of CMV retinitis re-
ceived another implant using the same surgi-
cal technique. The second implant was placed
in the inferior nasal quadrant. No patient
presented ocular complications due to this
procedure. The previously placed implants
were not removed.
Retinal detachment in these patients may
contribute to loss of vision. The rate of reti-
nal detachment in patients with CMV retini-
tis may be 15 to 29% and the cumulative
probability of this occurring one year after
the diagnosis of retinitis is 50%. Detachment
may occur in the contralateral eye of 46 to
67% of the patients (14). Anand et al. (33),
after treating 22 patients with intraocular
implants, reported an 11% rate of retinal
detachment which proved to be satisfactory
when compared to the 29% rate attributed to
previously reported viral action on the retina.
Martin et al. (35) found an 18% rate of
retinal detachment in CMV retinitis patients
who received the intraocular implant as the
first therapeutic modality.
In this study, 15.4% of the eyes devel-
oped retinal detachment. This rate is in agree-
ment with former studies and with the per-
centage of retinal detachment due to the
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destructive action of the cytomegalovirus
itself on the retina. There was no evidence
that the implant could have increased the
percentage of retinal detachment. The fact
that these patients presented a longer period
of exposure to the virus and several relapses,
in addition to extensive retinal involvement,
was also probably a risk factor.
In the present study, we chose to use
posterior vitrectomy with silicone oil injec-
tion and endolaser application for those pa-
tients who developed retinal detachment.
Results were good in 100% of the cases with
retina application. The implant led to heal-
ing of retinitis in patients who had unsuc-
cessfully received intravenous ganciclovir
and foscarnet. Possible reasons include higher
effectiveness of the local treatment with an
adequate and stable level of the drug, elimi-
nating the problem of compliance.
Some of the initially studied patients pre-
sented an already deteriorated ocular condi-
tion, probably with a short survival, and
received the implant due to the lower risk of
complications. The good result led to the use
of the procedure even in patients with better
vision. The initial experience reported in this
study is in favor of the use of prolonged
ganciclovir release ocular implants for the
treatment of CMV retinitis in AIDS patients.
The HIV epidemic was the major event
related to Medicine at the end of the 20th
century. After twenty years of its impact,
new diseases and clinical changes of associ-
ated diseases due to HIV have appeared.
CMV retinitis is an outstanding example.
Extremely rare before HIV, it became one of
the most important ocular public health prob-
lems responsible for great morbidity, suffer-
ing and blindness. Fortunately the emergence
of new antiretroviral and anti-CMV drugs
has changed the situation, increasingly im-
proving disease control.
Our data show that the surgical proce-
dure for the placement of prolonged ganci-
clovir release ocular implants is simple and
was not associated with clinically significant
complications. The implant was shown to be
efficient in preventing progression of CMV
retinitis even in patients previously and un-
successfully treated with intravenous drugs
(ganciclovir or foscarnet) for periods of up
to 8 months and to be a safe modality of local
treatment.
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